Stellanova Therapeutics

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable. Houston, June 3, 2021 – Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by …

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing Read More »